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Abstract
Background: Subpopulations of cancer cells with the capacity of generating solid tumors have been characterized.
In various cancer types, including prostate cancer cells, a side population (SP) and CD133-expressing cells have
been proposed as containing a population cancer cells with stem-like ability. Therefore the aim of this work was to
determine, in prostate cancer cell lines, the frequency and tumorigenic potential of SP and CD133+ cells.
Results: In vitro 2D colony-forming assay and sphere-forming assay, Flow cytometry analysis and magnetic cell
sorting were utilized to sort CD133+, CD133- and Side population (SP) cells. Our findings indicate that CD44 and
integrin a-6 are uniformly expressed in the hTERT cell lines; however, CD133 is expressed only in a small
population (< 0.1%). FACS-sorted CD133+ and CD133- cells exhibited similar tumorigenicity in vitro and in vivo.
Additionally, for the hTERT cells, SP rather than CD133 expression showed an 8-fold enhanced tumorigenic
potential. The data suggest that SP cells, rather than those with CD133 marker, contain the rare population of CSC
capable of producing prostate tumors.
Conclusion: Collectively, our data suggest that although CD133 is expressed only in a small population of hTERT-
immortalized prostate cancer cells, it is not likely to be associated with stem cells, as CD133- and CD133+ cells
exhibited similar tumorigenicity. However, SP isolated cells, appear to be enriched with tumorigenic stem-like cells
capable of generating palpable tumors.
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Introduction
Prostate cancer is the most commonly diagnosed malig-
nancy in men. At the time of diagnosis, approximately
50% of men have clinically advanced disease. Although
much effort has been directed toward treatment, no
therapy has been developed that effectively treats this
disease. The problem of treating prostate cancer is a
result of the persistence of cancer-initiating progenitor/
stem cells that are found in low frequency. A method
for identification of cancer stem cells (CSC) in prostate
cancer has not been established.
Several populations of cells have been considered as
prostate stem cells [1-4]. CD133, in combination with
other markers, was originally utilized to isolate hemato-
poietic stem cells [5,6] as well subpopulations in mam-
mary gland [7], brain [8], colon [9,10], pancreas [11],
and liver cells [12]. Although there is no known func-
tion for CD133, it is expressed by developing epithelial
cells and is rapidly down-regulated upon differentiation
[13-16]. CD133 selection has been used to enrich a
population of normal prostate epithelial cells capable of
forming acinar-like structures as xenografts, and to
derive a population of prostate cancer cells with a
higher tumorigenic capacity in vitro than its negative
counterpart [17]. However, use of CD133+ expression
for isolation of cancer-initiating progenitor or stem cells
is organ-specific and, for prostate cancer, is not directly
* Correspondence: hongbinsong@263.net; cyates@mytu.tuskegee.edu
1Department of Biology and Center for Cancer Research, Tuskegee
University, Tuskegee, AL 36088 USA
3Institute of Disease Control and Prevention, Academy of Military Medical
Science, Beijing, 100071, China
Full list of author information is available at the end of the article
Zhou et al. Molecular Cancer 2011, 10:112
http://www.molecular-cancer.com/content/10/1/112
© 2011 Zhou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.associated with a subpopulation capable of self-renewal
and tumorigenicity [18].
Some cancer cells have, on their cell surface, ATP-
binding cassette transporters (ABCG) that pump out the
DNA-binding dye, Hoechst 33342 [19]. These cells are
resistant to toxic agents and survive longer than cells
committed to differentiation. This subset of cells has
been characterized as a side population (SP). SP cells
are composed of a rare (0.01-5%) and heterogeneous
population that varies with tissue type and stage of
development [20,21]. SP cells derived from patients and
from metastatic cell lines, exhibit enrichment in stem/
progenitor cells or CSC/progenitor cells, particularly in
cases where the tissue-specific stem cell markers are not
established [22]. Numerous cancer models including
hematopoitic, pediatric, ovarian, and prostate cancers
have investigated the tumorgenic potential of SP cells
[23,24].
Since a cell culture model that closely mimics the
pathophysiological conditions of primary prostate tumor
development is essential to understanding the genera-
tion of tumors from CSCs, we have utilized a newly
developed panel of hTERT-immortalized primary pros-
tate cancer cell lines, which are similar to non-immorta-
lized primary prostate cancer cells [25]. The hTERT-
immortalized lines were generated from primary human
tissues representative of most prostate cancer cases [26].
This study focused on the “cancer stem cell hypoth-
esis,” which indicates that primary tumors originate
from a minor population of cells. With a panel of
hTERT immortalized cell lines, CD133 expression and
SP were investigated to determine which population of
cells is associated with higher tumorigenicity. The
results indicate that, although CD133 is expressed only
in a small population (< 0.1%) in the hTERT cell lines,
CD133+ and CD133- cells exhibited similar tumorigeni-
city in vitro and in vivo. Additionally, in our hTERT-
immortalized cell lines, SP cells, but not those with
CD133 expression, showed an 8-fold higher tumorigenic
potential. Thus, SP cells apparently contain the popula-
tion of CSCs capable of forming prostate tumors.
Results
Prostate cancer cells are inefficient at generating spheres
in vitro and xenograft tumors in vivo
A major characteristic of CSC cells, is their capacity to
form three-dimensional structures, or spheres. Thus, we
utilized a non-adherent sphere-forming assay to evaluate
a panel of hTERT-immortalized human primary prostate
cancer cell lines. The assays indicated that the hTERT-
immortalized cells contain a minor population, account-
ing for about 1% of the total, with sphere-forming capa-
city (Figure 1A). Further, the serial passaging capability
of RC-58T/hTERT/SA#4-D spheres was determined.
Cells isolated from prostate spheres (prostaspheres)
were serially passaged for multiple cycles (Figure 1B),
implying that the sphere-initiating cells have self-
renewal capability. As controls, non-tumorigenic
hTERT-immortalized prostate cell lines RC-58T/h/
SA#4-k, RC-165N/hTERT, and PrEC-6 were also tested.
Each of these cell lines demonstrated limited serial pas-
saging capabilities (additional file 1).
The rarity of prostasphere formation implied the exis-
tence of a minor population of self-renewing cells, we
sought to determine if this extended to the generation
of tumors in NOD/SCID mice. The limiting dilution
assay [27,28] was used to determine the frequency of
cells responsible for colony or xenograft generation. In
this manner, the tumorigenic potential of RC-193a/
hTERT, SCID5080A-1 and RC-58T/hTERT/SA#4-D
cells was determined. Generation of palpable tumors
required about 12,735 RC193a/hTERT cells; 7,399
SCID5080A-1 cells; 1,799 RC-58T/hTERT/SA#4-D cells
cultured in conventional monolayers; or 1,425 RC-58T/
hTERT/SA#4-D cells from non-adherent cultured
spheres (Figure 1C). Thus, large numbers of cells were
required to generate detectable tumors, indicating that
prostate tumor growth in vivo is an inefficient biological
process. RC-58T/hTERT/SA#4D cells generated tumors
at significantly lower frequency than RC-193a/hTERT
and SCID5080A-1 cells., Non-tumorigenic hTERT-
immortalized prostate cell lines RC-58T/h/SA#4-k, RC-
165N/hTERT, and PrEC-6 did not give rise to xenograft
tumor in mice with comparable large number of cells
injection (data not shown).
Since RC-58T/hTERT/SA#4D generated tumors as the
lowest frequency, we further sought to determine the
expression of several known stem cell markers, Oct 3/4,
p63 and ABCG2, before and after in vivo inoculation.
There was increased Oct 3/4, with similar expression of
p 6 3e x p r e s s i o n ,A B C G 2 ,t u m or suppressor, PTEN, and
prostate specific cell antigen (PSCA). We did not
observe expression of androgen receptor (AR) (addi-
tional file 2). In all these findings suggest that cultured
cells and xenograft tumors display similar
characteristics.
CD133 does not represent an effective marker for CSCs in
hTERT-immortalized prostate cancer cells in vitro or in
vivo
Additional markers, including CD44, a6i n t e g r i n ,a n d
CD133, are associated with enrichment of CSCs [29,30].
Since, of these, CD133, the most characterized, is found
in enriched fractions of CSCs in several types of cancer
tissues (brain, colon, pancreas, and prostate) [17], the
expression levels within our panel of hTERT-immorta-
lized prostate cancer cells were determined. As shown
by FACS and immunofluorescence analysis of the cell
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Page 2 of 13Figure 1 Tumorigenicity of hTERT-immortalized cells under non-adherent culture conditions and formation of xenograft tumors.A )
hTERT-immortalized epithelial cells lines (RC-58T/hTERT/SA#4-D, RC-92a/hTERT, SCID5083-6, RC-193a/hTERT, and SCID5080A-1, RC-58T/h/SA#4-k,
RC-165N/h, PrEC-6) from prostate cancer or non-cancer patients form spheroid structures (called here prostaspheres). The images were taken at
100 × magnification. B) Prostaspheres were serially passaged under non-adherent culture conditions. RC-58T/hTERT/SA#4-D was passaged 10
times without showing a decline in sphere forming capability. The passaging capacities of prostaspheres from RC-92a/hTERT, SCID5083-6, RC-
193a/hTERT, and SCID5080A-1 were tested for three generations (n = 6; error bars indicate the standard deviation of sphere-forming efficiency
for each type of cell line). C) Xenograft tumor generation with RC193a/hTERT, SCID5080A-1, RC-58T/hTERT/SA#4-D cells cultured as monolayers
required large numbers of injected cells. The error bars indicate the lower and upper limits of the confidence interval based on the limiting
dilution calculation.
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Page 3 of 13lines, CD133 expression was rare (Figure 2A), amount-
ing to > 0.1% of the cell population (Figure 2B). In con-
trast, expressions of the cell surface markers, CD44 and
a6 integrin, were high and universal (Additional file 3).
Thus, CD133 appears to be associated with a minor cell
population and could represent the most tumorigenic
cells.
To determine the role of CD133+ cells versus CD133-
cells, double FACS sorting was used to ensure enrich-
ment the CD133+ cells from the RC-58T/hTERT/SA#4-
D cell line. CD133+ and CD133- cells were evaluated
for formation of two-dimensional (2D) monolayer colo-
nies and for formation of prostaspheres. CD133- cells
gave rise to significantly more prostaspheres in mono-
layer cultures and in non-adherent cultures (P < 0.05)
(Figure 3A, B). To characterize further the tumorigenic
potential of the CD133+ fraction over CD133- fraction,
both were directly inoculated into NOD/SCID mice.
CD133- cells displayed higher tumorigenicity (Figure
3C). Quantitatively, CD133+ fractions have a 1/28,854
frequency of generating tumors compared to a 1/3,002
frequency for CD133- fractions in RC-58T/hTERT/
Figure 2 CD133 phenotyping of hTERT-immortalized prostate cancer cell lines. RC-58T/hTERT/SA#4-D, RC-92a/hTERT, RC-193/a/hTERT and
their xenograft tumor-derived cell lines SCID5083-6, SCID5080A-1 were analyzed for CD133. A). CD133 expression by immunofluorescence
utilizing primary CD133 antibody, and Alexa Fluor-594 secondary antibody (yellow). Arrows indicate staining for cell surface molecules. B) CD133
expression by FACS sorting utilizing CD133 antibody conjugated with PE. Indicated within each panel is the percentage of CD133+ cells
contained in each cell line.
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Page 4 of 13Figure 3 Lack of enhanced tumorigenicity of CD133+ enriched cells. A). Double FACS sorted CD133+ subpopulations were assayed for
colony-forming advantage relative to the CD133- subpopulation. A) 2D colony-forming assay or B) sphere-forming assay. Data are expressed as
means ± standard deviations. Statistical comparisons are with the CD133+ subpopulation, *P = 0.1; **P < 0.05. C). Schematic depiction of assay
in mice with CD133-fractioned RC-58T/hTERT/SA#4-D cells as a representative of all tested hTERT-immortalized primary prostate cancer cell lines.
In NOD-SCID mice, CD133- cells generated larger tumors than CD133+ cells. D). Formalin-fixed, paraffin-embedded tissues were obtained from
xenograft tumors. Individual tissues sections were stained with H&E or human specific primary PSCA antibody, and Alexa Fluor-594 secondary
(red) and Dapi (blue) nuclear stain. Scale bar indicates 40 μM.
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Page 5 of 13SA#4-D (Figure 3C and Table 1). This trend was con-
firmed, under similar conditions, for fractions in RC-
193/hTERT (CD133+, < 1/24,836 and CD133-, 1/
14,244) and SCID5080A-1 (CD133+, 1/5,586 and
CD133-, 1/1468). To confirm that these tumors where
of human and prostate origin we performed H&E stain-
ing and immunofluorescence staining utilizing human
specific prostate specific stem cell antigen (PSCA) anti-
body. PSCA expression was significantly expressed in
xenograft tumor cells and staining was not observed in
the cells of surrounding stroma (Figure 3D). Addition-
ally, secondary antibody alone did not reveal any posi-
tive staining (data not shown). Thus, it appears that, in
this model system, CD133 expression is not sufficient to
determine the tumorigenic potential of prostate cancer
cells.
SP isolated cells have higher tumorigenicity than CD133+
cells in hTERT immortalized prostate cancer cells
Since CD133 expression failed to determine tumorigeni-
city, we asked if there existed a minor cell population,
representing the CSCs in the hTERT cells. Since SP ana-
lysis has been used to identify stem cell populations
[2,31-33], we examined the SP of RC-58T/hTERT/
SA#4-D cells, since this line gave rise to subcutaneous
x e n o g r a f tt u m o r si nN O D / S C I Dm i c ei nas h o r t e rt i m e
relative to other hTERT-immortalized cell lines. Utiliz-
ing 5 μg/ml of Hoechst 33342 or DyeCycle Violet
(DCV), we determined that 1.47% of the RC-58T/
hTERT/SA#4-D cell population was positive and verapa-
mil-sensitive (Figure 4A, B). Xenograft tumor growth
indicated that SP-isolated cells showed increased
tumorigenic frequency (6~8 fold) over non-SP cells
(Table 2). SP cells also formed larger xenograft tumors
in a shorter time than non-SP cells. The SP “arm” was
divided into three portions, SP
low,S P
mid,a n dS P
hi (Fig-
ure 5A), to determine the tumorigenicity of each popu-
lation of cells. This fractionation into sub-groups did
not yield a significant tumorigenic enhancement, i.e.,
SP
low (7.37-fold), SP
mid (6.55-fold), and SP
hi (7.98-fold),
over non-SP cells, although the tumors generated by
SP
low were larger than those generated by other SP frac-
tions (Figure 5B). Additionally, in some cases, non-SP
cells gave rise to small xenograft tumors (data not
shown). Immunofluorescence staining for human speci-
fic PSCA expression, confirmed tumors were human
and of prostate origin as well (Figure 5C).
Since SP enriched population isolated cells indicated
tumorigenicity, we further sought to characterize CD133
expression in the non-SP and SP cells. Interestingly,
2.3% of cells were CD133+ in non-SP sorted cells,
which is similar to findings in Figure 2, however there
was only 1.5% of cells that were CD133+ in the DCV
sorted SP cells (Additional file 4). The results indicate
Table 1 Tumorigenicity of CD133+ or CD133- Fractions in
hTERT immortalized cell lines.
RC-58T/hTERT/SA#4-D
Cell Types Cell number Incidence Estimated frequency
CD133+
(n = 23)
100 0/3 1/28,854
(1/3,908 ~ 1/213,084)
500 0/3
1,000 0/4
2,000 0/4
5,000 0/3
10,000 0/4
20,000 1/2
CD133-
(n = 23)
100 0/3 1/3,002
(1/1,408 ~ 1/6,401)
500 0/3
1,000 2/4
2,000 4/4
5,000 2/3
10,000 3/4
20,000 2/2
RC-193a/hTERT
CD133+
(n = 16)
100 0/4 < 1/24,836
500 0/4
1,000 0/4
10,000 0/2
24,000 0/2
CD133-
(n = 24)
100 0/4 1/14,244 (1/5,880~1/34,508)
500 0/4
1,000 0/8
10,000 3/6
24,000 2/2
SCID5080A-1
CD133+
(n = 19)
100 1/4 1/5,586 (1/1,901~1/16,419)
500 1/3
1,000 1/4
2,000 2/4
18,000 1/2
30,000 2/2
CD133-
(n = 19)
100 2/4 1/1,468 (1/614~1/3,365)
500 2/3
1,000 1/4
2,000 2/4
18,000 2/2
30,000 2/2
For hTERT-immortalized human primary prostate cancer cell line RC-58T/hTERT/SA#4-
D, NOD/SCID mice were killed at 16 weeks post-injection. For RC-92a/hTERT, mice
were killed at 23 weeks post-injection since RC-92a/hTERT xenograft tumor grows very
slowly. For SCID5083-6, mice were killed at 16-17 weeks post-injection. For RC-193a/
hTERT, mice were killed at 15-23 weeks post-injection. For SCID5080A-1, mice were
sacrificed at 15-23 weeks post-injection. Mice were considered positive if palpable
tumor tissue was identified. All the doses except that only resulted in negative mice
were used to calculate the limiting dilution experiments. Confidence interval was
displayed in the bracket. SCID5083-6 and SCID5080A-1 xenograft tumors grows faster
than its parental RC-92a/hTERT, RC-193a/hTERT xenograft tumors, respectively.
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Page 6 of 13that, while SP isolation provides enrichment of the CSC
population. Further characterization of additional mar-
kers associated with SP is warranted.
Discussion
A small subset of cancer cells may be responsible for
tumor development and recurrence after therapy. In
prostate cancer, there appears to be a subset of cancer
cells, with properties of adult stem cells [1], that can
self-renew and generate differentiated cancer cells with
limited proliferative potential. In addition, CSCs, which
are rare, are considered to possess chemoresistance and
teleomerase activity and to have specific gene signatures
and signal pathway activities [34]. Since cancers are het-
erogeneous and all cells do not behave in the same
manner, the cancer stem cell theory provides a plausible
explanation to these events. CSCs or stem-like cancer
cells originate from a small fraction of cells. They have
the capacities of self-renewal, and chemoresistance, and
they give rise to large numbers of cells within the tumor
mass [35]. The hypothesis that the tumors originate
from a minor cell subset with stem cell characteristics
has been demonstrated by studies with breast, brain,
prostate, and other solid tumors [4,7,8,11]. Furthermore,
CSCs have been suggested to be responsible for tumori-
genicity, progression, and metastasis in cancers [36].
Therefore, identification and characterization of this
population of cells is needed to understand their charac-
teristics and to develop treatment strategies targeting
this small population [37].
Efforts have been made to determine the physical
markers associated with CSCs [38]. For prostate cancer,
there has been difficulty in harvesting quality samples of
tissues and in generating cell lines for research purposes.
LNCaP, DU145, PC3 (PPC1), and 22Rv1 are most popu-
larly as cell culture models. These cells are all isolated
from metastatic patients and thus are not useful for
determining development of primary tumors. To
Figure 4 SP in RC-58T/hTERT/SA#4-D cells. A) RC-58T/hTERT/SA#4-D cells were analyzed for SP based on Hoechst 33342 (Sigma) or DCV
staining. The RC-58T/hTERT/SA#4-D SP cells represent 1.47% of the entire population. B) 0.42% of the RC-58T/hTERT/SA#4-D SP as inhibited by
50 μM verapamil.
Zhou et al. Molecular Cancer 2011, 10:112
http://www.molecular-cancer.com/content/10/1/112
Page 7 of 13determine the CSC population capable of generating
tumors, we utilized a panel of hTERT immortalized cell
lines. Initially, we determined that all hTERT immorta-
lized cells have sphere-forming capacity and that they
can be serially passaged. These findings are similar to
those for previously established, immortalized hTERT
prostate cells [39] and for prostate clinical samples [40].
Since, to date, there have been no reports of how this
translates into tumor growth in vivo,b u l kp o p u l a t i o n
cells or only sphere-forming cells were inoculated into
NOD/SCID mice. Among these populations, there was
no difference in tumor formation (Table 1). Molecular
characterization of the protospheres before and after in
vivo inoculation showed similar expression levels of
CD44, Oct 3/4, p63. Further characterization of prostate
specific markers showed AR expression is absent, how-
ever there was robust expression of PSCA. Several
reports have identified these markers, including the lack
of AR expression to be associated with prostate cancer
stem cells [41] (Supplemental Figure 1), which further
suggest that sphere-forming capacity or generally uti-
lized molecular makers typically associated with minor
cell population, do not completely characterize the CSC
population. Furthermore, our use of multiple cell lines
decreases the possibility of distinct cell line characteris-
tic as an explanation of these results.
Consistent with the stem cell hypothesis, which indi-
cates that only a minor fraction of cells are capable of
generating tumors, CD133 expression was observed, by
immunofluorescence and FACS, only in a minor fraction
of cells, > 1% of the population. As determined with
FACS-sorted CD133
+ and CD133
-RC-58T/hTERT/
SA#4-D cells, CD133 expression did not have an influ-
ence on the capacity of cells to form prostaspheres or
on tumor development in SCID mice. In fact, CD133-
cells formed larger prostaspheres and larger tumors in
mice. Similarly, Shmelkov and colleagues [42] reported
that, for a mouse model of colon cancer, the CD133
+
and CD133
- tumor subpopulations formed colono-
spheres in vitro and were tumorigenic in a mouse
model involving NOD/SCID serial xenotransplantation,
with CD133
- cells forming more aggressive tumors [42].
The present results and those by Shmelkov et al. are
contradictory to reports from Miki [29] and Goodyear
[39], that hTERT-immortalized prostate cells containing
a CD133
hi subpopulation (< 3.3%), in contrast to
CD133
lo cells, generated prostaspheres in vitro and dys-
plastic lesions in NOD-SCID mice [39]. Interestingly,
however only cells from CD133
hi prostaspheres, but not
CD133
hi single cells, were capable of generating dysplas-
tic lesions. Since CD133
+ cells have been reported to
give rise to CD133
- cells [8,10], suggest that additional
CD133
lo cells are required to support growth in vivo
and that CD133 cells alone are not capable of generat-
ing tumor development.
Since CD133 expression did not determine the
tumorigenic potential of RC-58T/hTERT/SA#4-D cells,
we utilized SPs, which allows isolation of a small popu-
lation of cells that differentially pump out the fluores-
cent dye, Hoechst 33342, by the pump proteins, ABC
transporters, on the cell surface [43], as a second
method to determine the minor population capable of
developing tumors in mice. For RC-58T/hTERT/SA#4-
D cells, the results suggested successfully isolation of
minor populations of cells, SP
low,S P
mid, and SP
hi (Figure
5). This was confirmed with displacement with 50 μM
verapamil (Figure 4A). After inoculation of SP
low,S P
mid
and SP
hi populations of isolated cells into NOD/SCID,
SP
low-enriched prostate cancer cells developed tumors
(Table 2). Although SP
mid and SP
hi isolated cells also
developed tumors, SP
low cells developed tumors at a fas-
ter rate, and tumor size was significantly larger (Table 2,
Figure 5). This suggested that SP, in contrast to CD133
expression is useful in determining the population of
cells capable of giving rise to tumors.
Our results show that tumors at different clinical
stages are heterogeneous. Nevertheless, CSC identified
in cultured cancer cells could be identified in intact ani-
mals. Furthermore, our findings suggest that SP is a
more appropriate method for determining the tumori-
genic potential of small populations of cells, as both SP
and non-SP cells express a similar percent of CD133+
Table 2 In vivo Tumorigenicity of Side Population
Isolated cells
RC-58T/hTERT/SA#4-D
Cell
Types
Cell
number
Incidence Combined Estimated
frequency
SP
low 1,000 2/5 1/3,522
(n = 18) 5,000 2/4 (1/1,661~1/7,466)
10,000 6/6
50,000 3/3
SP
mid 1,000 1/5 1/3,963
(n = 15) 5,000 4/4 (1/1,762 ~1/8,914)
10,000 3/4
50,000 2/2
SP
hi 1,000 2/4 1/3,252
(n = 14) 5,000 4/4 (1/1,356~1/7,805)
10,000 2/3
50,000 2/2
Non- 1,000 1/4 1/25,952
SP 5,000 3/4 (1/9,762~1/68,998)
(n = 14) 10,000 1/3
50,000 1/3
** Mice were killed at 15-17 weeks post-injection. All the cell doses, excluding
negative mice, were used to calculate the limiting dilution experiments. 95%
confidence interval was displayed in the bracket. Combined Frequency for SP
= 1/3,574 (1/2,243~1/5,695)
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Page 8 of 13expressing cells. Thus further characterization of this SP
population is warranted. SP cells have been identified in
several tumor cell lines [33,44,45] as well as in fresh
tumor samples [46-48]. There are, however, few reports
of their presence in prostate cancer. However, work
with prostate and breast cancer cells shows that
ABCG2-positive and -negative cells have similar tumori-
genicity [2]. Further, a recent report concerning DU-145
and PC-3 cells showed that SP cells contain a large
CD133+ population [22]. Although there was no charac-
terization of the tumorigenicity of this population, the
results highlight the fact that further characterization of
Figure 5 Analysis of SP and non-SP used for cell isolation and for animal experiments. A) RC-58T/hTERT/SA#4-D cells were subjected to
Hoechst 33342 dye and separated into SP
low,S P
mid, and SP
hi fractions B). Individual SP fractions were then injected subcutaneously and assayed
for tumorigenicity, after 100 days in NOD-SCID mice. Tumors were subsequently measured for tumor volume as shown by schematic
representing xenograft tumors. D). Formalin-fixed, paraffin-embedded tissues were obtained from SP generated xenograft tumors. Individual
tissues sections were stained with H&E or human specific primary PSCA antibody, and Alexa Fluor-594 secondary (red) and Dapi (blue) nuclear
stain. Scale bar indicates 40 μM.
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Page 9 of 13the SP with physical markers such as CD133 will aid in
the discovery of tumor-initiating CSCs.
Apparently, numerous factors determine the tumori-
genic potential of putative stem cells, and xenografts
tumor models are essential for complete characterization
of the tumor-initiating CSC. Identification of a subset of
CD133-expressing CSCs from human cancer samples
may not be ideal. Contributing to tumor growth in ani-
mals are various factors, such as the tumor microenvir-
onment and transplantation site. These should be well
controlled, and results should be cautiously interpreted
considering the physiological conditions of organ-speci-
fic development of tumors. Studies with multiple cancer
types, including melanomas, suggesting an association
between CSC frequency and a particular marker with
tumorigenic potential should be reassessed with opti-
mized experimental conditions, especially in a assay
involving intact animals [49,50]. It is essential to identify
the physical markers and experimental conditions that
initiate tumors in patients.
Conclusion
Prostate cancer is difficult to treat, for its stem cells are
poorly defined and therefore are untargeted. This report
presents evidence, that through quantitative assays in
intact animals, that SP is responsible for the population
of cells necessary for tumor development.
Materials and methods
Cell samples and culture
RC-58T/hTERT/SA#4-D, RC-58T/h/SA#4-k [51], RC-
92a/hTERT [29], RC-193-a/hTERT, RC-165N/hTERT
[52], and PrEC-6 [53] cell lines were generated by
hTERT-immortalization of primary human prostate can-
cer or benign tissues from different patients. SCID5083-
6 and SCID5080A-1 are cell lines from xenograft
tumors induced by RC-92a/hTERT cells [29] and RC-
193a/hTERT cells, respectively. The basic procedures for
establishing and characterizing prostate cell models have
been described [54]. Passage number for individual frac-
tions of cells are indicated as follows: RC58T/h/SA#4(D)
SP and Non-SP p17 RC58T/h/SA#4(D) p17 CD133-
RC58T/h/SA#4(D) p17 CD133+ RC193 p2 CD133+
RC193 p2 CD133- SCID5080A-1 p8 CD133-
SCID5080A-1 p8 CD133+
Most cells lines were cultured in serum-free keratino-
cyte medium (Invitrogen) and only RC-58T/hTERT/
SA#4-D were cultured with DMEM plus 10% serum and
insulin (2 μg/ml, Sigma).
In vitro 2D colony-forming assay
Cells, plated at a density of 300 cells/ml in 12-well tissue
culture plates (Corning), were fixed with 4% paraformal-
dehyde (PFA) for 20 min at room temperature and
stained with a mixture of 1% Nile blue and 1% rhoda-
mine B (in water). Colonies larger than 1 mm in dia-
meter were counted.
Sphere-forming assay
Non-adherent cultures were conducted as described
[55]. Briefly, cells were plated in 6-well, ultra-low attach-
ment plates (Corning) at a density of 1000 cells/ml.
After 2-3 weeks, prostaspheres were collected by centri-
fugation at 800 rpm and dissociated in 0.05% trypsin,
0.53 mM EDTA (Invitrogen) for 10 min and by use of a
plastic pipette to disrupt the spheres into single cells
mechanically. They were then passed through a 40-μm
mesh filter (BD Biosciences). The frequency of sphere-
forming were calculated by the number of observed
spheres divided by the initial number of seeding cells.
SP and cell sorting
The SP analysis based on Hoechst 33342 (Sigma) or
DCV (Invitrogen) staining was performed as previously
described [2,56,57]. For instruments equipped with vio-
let laser, DCV was substituted for Hoechst 33342 SP,
since it has emission characteristics and cell permeabil-
ity similar to Hoechst 33342, but with longer wavelength
excitation maxima. Briefly, cells were collected with
Accutase (Millipore) from culture flasks and re-sus-
pended in warm culture medium (10
6 cells/ml). Hoechst
33342 was added at a final concentration of 10 μg/mL,
and cells were incubated at 37°C for 2 h with intermit-
tent mixing. For DCV staining, DCV (10 μM final con-
centration) was added to cultures, and the cells were
incubated for 30 min. As control reactions, verapamil
(Sigma) was added at a final concentration of 50 μg/ml
in the presence of Hoechst 33342. After incubation,
cells were washed once and re-suspended in ice-cold
Hanks’ balanced saline solution (Invitrogen) containing
2% fetal bovine serum (Invitrogen) and 2 mM HEPES
buffer (Invitrogen). Cells were stained with 7-aminoacti-
nomycin D (7-AAD, 2 μg/ml, Sigma) to determine viabi-
lity, then analyzed and sorted by flow cytometry using
FACS Vantage DiVa (Becton Dickinson), FACS Vantage
SE or Accuri Flow cytometer.
Flow cytometry analysis and magnetic cell sorting
Routine flow cytometry analysis was performed with
FACS Calibur and a BD LSR II flow cytometer (BD
Biosciences). CD44 (Millipore), a6 integrin (R&D), and
CD133 antibody conjugated with phycoerythrin (PE) or
anti-allophycocyanin (Miltenyi Biotec) were used. For
the population analyses, at least 100,000 events were
acquired for each sample, and all cells positive for 7-
AAD were gated out. For the magnetic cell sorting, RC-
58T/hTERT/SA#4-D cells were collected by Accutase
(Millipore) digestion and magnetically labeled and
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or indirect isolation Kit (Miltenyi Biotec) according to
manufacturer’s instruction. CD133+ cells constituted
15.98% of the magnetically sorted viable cells as deter-
mined by flow cytometry and where utilized directly
without sub-passaging for assays in vitro and in vivo.
Immunostaining
Indirect immunostaining was used to detect expression
of the cell surface marker. Briefly, cytospined cells were
fixed with 4% PFA in phosphate-buffered saline (PBS)
for 10 min at room temperature and, after washing with
PBS, blocked with 10% goat whole serum in PBS. After
washing, cells were incubated sequentially with mono-
clonal antibody anti-CD133 (Miltenyi Biotec), Alexa
Fluor-594, or 546-conjugated goat-anti-mouse secondary
antibody (Invitrogen), and 4’,6-diamidino-2-phenylindole
(Sigma), with washings after each step. They were then
placed in mounting medium (Vector). Images were
acquired and analyzed with the Zeiss Axio fluorescence
imaging system (Carl Zeiss MicroImaging Inc.) in the
Tuskegee University Imaging Facility.
Immunohistochemistry
PSCA staining in prostate xenografts in mice was ana-
lyzed in formalin-fixed, paraffin-embedded tissues. Indi-
vidual tissue sections were then incubated with
Hematoxylin and Eosin (H&E) stain or blocked with 3%
BSA, 5% NGS, PBS 1-2 hrs. Polyclonal antibody against
human specific PSCA (H-83; SCBT) at 1:50 dilution in
3%BSA, 5% NGS, PBST was then applied at RT for 1 h.
Secondary anti-rabbit Alexa Fluor-594 (red) was utilized
at 1:100 for 1 h, and a counterstain Dapi (blue) was
applied.
Assay of tumorigenicity in intact animals and limiting
dilution analysis
NOD/SCID mice were purchased from the Animal Pro-
duction Area of the National Cancer Institute-Frederick
Cancer Research and Development Center (Frederick,
Maryland) and maintained in a barrier facility approved
by the American Association for Accreditation of
Laboratory Animal Care. For injection of cells, a pre-
viously published method [2,58] was used. Briefly, 100
μl of cells in their regular culture medium and 100 μlo f
Matrigel (BD Biosciences) were mixed and injected sub-
c u t a n e o u s l yi n t om i c e( 4 - 8w e e k so l d ) .A l lm i c ew e r e
euthanized when the tumor measured 2 cm or between
15 and 26 weeks post-transplantation or when their
health ice was threatened. Calculations were based on
the limdil function in the statmod package, which is
part of R statistical package. The process was executed
online http://bioinf.wehi.edu.au/software/limdil/index.
html.
Statistical analysis
Group differences were determined by unpaired Stu-
dent’s t-test. P values of < 0.05 were considered
significant.
Additional material
Additional file 1: Non-tumorigenic hTERT-immortalized prostate cell
line show limited serial passaging. Table summarizes the serial
passaging threshold for RC-58T/h/SA#4-k, RC-165N/hTERT, and PrEC-6
cells, respectively.
Additional file 2: Specific Markers for RC-58T/hTERT/SA#4-D. Analysis
of RT-PCR products for Oct 3/4, ABCG2, PTEN, PSCA, and AR were
generated from RC-58T/hTERT/SA#4-D cells and corresponding xenograft
derived tumors. GAPDH served as internal control. Figure shown is
representative data from experiments formed in triplicate, and multiple
xenograft tumors.
Additional file 3: CD44 and Integrin a6 phenotyping of hTERT-
immortalized prostate cancer cell lines. RC-58T/hTERT/SA#4-D, RC-193/
a/hTERT and their xenograft tumor-derived cell lines SCID5083-6,
SCID5080A-1 were analyzed for CD44 and integrin a6. A). CD44
expression was determined by immunofluorescence utilizing primary
CD44 antibody, and Alexa Fluor-594 secondary antibody (red). Arrows
indicate staining for cell surface molecules. B) CD44 and integrin a6
expression was determined by FACS sorting utilizing CD44 or integrin a6
antibody conjugated with PE, respectively.
Additional file 4: Percentage of CD133 expressing cells in the Side
Population and non-Side Population FACS sorted cells. RC-58T/
hTERT/SA#4-D cells were analyzed for CD133 expression in SP or non-SP
sorted cell populations. A.) The percentage of the non-side population
(SP) cells expressing CD133 was determined utilizing CD133 PE-
conjugated antibody. B.) The percentage of DCV FACS sorted (SP) cells
expressing CD133 was determined utilizing CD133 PE-conjugated
antibody. Indicated within each panel is the percentage of CD133+ cells.
C.) Table summarizing the percentage of cells in the non-SP and SP cell
fractions that express CD133 positivity.
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